AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations

Aumolertinib (formerly almonertinib; HS-10296) is a novel third-generation epidermal growth factor receptor tyrosine kinase inhibitor approved in China. This double-blind phase III trial evaluated the efficacy and safety of aumolertinib compared with gefitinib as a first-line treatment for locally a...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Shun, Dong, Xiaorong, Jian, Hong, Chen, Jianhua, Chen, Gongyan, Sun, Yuping, Ji, Yinghua, Wang, Ziping, Shi, Jianhua, Lu, Junguo, Chen, Shaoshui, Lv, Dongqing, Zhang, Guojun, Liu, Chunling, Li, Juan, Yu, Xinmin, Lin, Zhong, Yu, Zhuang, Wang, Zhehai, Cui, Jiuwei, Xu, Xingxiang, Fang, Jian, Feng, Jifeng, Xu, Zhi, Ma, Rui, Hu, Jie, Yang, Nong, Zhou, Xiangdong, Wu, Xiaohong, Hu, Chengping, Zhang, Zhihong, Lu, You, Hu, Yanping, Jiang, Liyan, Wang, Qiming, Guo, Renhua, Zhou, Jianying, Li, Baolan, Hu, Chunhong, Tong, Wancheng, Zhang, Helong, Ma, Lin, Chen, Yuan, Jie, Zhijun, Yao, Yu, Zhang, Longzhen, Jie, Weng, Li, Weidong, Xiong, Jianping, Ye, Xianwei, Duan, Jianchun, Yang, Haihua, Sun, Meili, Sun, Changan, Wei, Hongying, Li, Chuan, Ali, Siraj M., Miller, Vincent A., Wu, Qiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509093/
https://www.ncbi.nlm.nih.gov/pubmed/35580297
http://dx.doi.org/10.1200/JCO.21.02641

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509093/
https://www.ncbi.nlm.nih.gov/pubmed/35580297
http://dx.doi.org/10.1200/JCO.21.02641

Ejemplares similares